A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Müller Cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The pathologies of numerous retinal degenerative diseases can be attributed to a multitude of genetic factors, and individualized treatment options for afflicted patients are limited and cost-inefficient. In light of the shared neurodegenerative phenotype among these disorders, a safe and broad-based neuroprotective approach would be desirable to overcome these obstacles. As a result, gene delivery of secretable-neuroprotective factors to Müller cells, a type of retinal glia that contacts all classes of retinal neurons, represents an ideal approach to mediate protection of the entire retina through a simple and innocuous intraocular, or intravitreal, injection of an efficient vehicle such as an adeno-associated viral vector (AAV). Although several naturally occurring AAV variants have been isolated with a variety of tropisms, or cellular specificities, these vectors inefficiently infect Müller cells via intravitreal injection. METHODOLOGY/PRINCIPAL FINDINGS: We have previously applied directed evolution to create several novel AAV variants capable of efficient infection of both rat and human astrocytes through iterative selection of a panel of highly diverse AAV libraries. Here, in vivo and in vitro characterization of these isolated variants identifies a previously unreported AAV variant ShH10, closely related to AAV serotype 6 (AAV6), capable of efficient, selective Müller cell infection through intravitreal injection. Importantly, this new variant shows significantly improved transduction relative to AAV2 (>60%) and AAV6. CONCLUSIONS/SIGNIFICANCE: Our findings demonstrate that AAV is a highly versatile vector capable of powerful shifts in tropism from minor sequence changes. This isolated variant represents a new therapeutic vector to treat retinal degenerative diseases through secretion of neuroprotective factors from Müller cells as well as provides new opportunities to study their biological functions in the retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 rAAV6 N451D expression following intravitreal injection. Confocal imaging of immunostained transverse retinal sections 3 weeks post-injection of rAAV6 N451D dsCAG-GFP (B, C). GFP expression analysis (B) and overlay with GS (C) reveal this mutant to be sufficient for an intravitreal Müller infection, though at a reduced efficiency relative to ShH10 (fig. 1D, F). Mapping of this mutation onto the AAV6 capsid subunit VP3 (A) (blue) shows its location near the three-fold axis of symmetry of the assembled capsid. Three-dimensional models of the AAV6 VP3 subunit were generated using Swiss Model with the coordinates of AAV2 (Protein Databank accession no. 1LP3) supplied as a template and images were rendered in Pymol and Rasmol. Additionally, the D532N mutation (green) maps near the HSPG-binding domain (purple) [35].](https://figures.cochat.ai/paper-figures/a1b918ae052e44d5bf5134ffbd3eb284/a-novel-adeno-associated-viral-variant-for-efficient-and-selective-intravitreal-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent work has developed AAV variants that are capable of infecting both Muller glia and photoreceptors across the retina following intravitreal administration, making intravitreal injections a promising alternative.24,25”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An example are the rAAV6 variants ShH10 and ShH10-Y445F that efficiently infect rat, mouse, and human Müller glial cells [60,62,272].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [272]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129 · cited 1×
“analogous roles in the CNS [26,27,36,37].”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“The therapeutic potential of AAV-mediated gene delivery to the retina has best been illustrated by the positive results from three phase I clinical trials for Leber’s Congenital Amaurosis (LCA), a rare autosomal recessive blinding disease caused by loss of function mutations in the visual cycle enzyme retinol isomeras…”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“The therapeutic potential of AAV-mediated gene delivery to the retina has best been illustrated by the positive results from three phase I clinical trials for Leber’s Congenital Amaurosis (LCA), a rare autosomal recessive blinding disease caused by loss of function mutations in the visual cycle enzyme retinol isomeras…”
BackgroundMüller cells in the healthy and diseased retina
BRINGMANN, A., PANNICKE, T., GROSCHE, J., FRANCKE, M., WIEDEMANN, P., SKATCHKOV, S., OSBORNE, N., & REICHENBACH, A. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.05.003 · Cited by 1,711 · cited 1×
“Müller cells serve numerous, significant physiological functions in the retina including but not limited to: metabolic support of neurons, K and water homeostasis, free radical scavenging and oxidative protection, neurotrophic secretion, and neurotransmitter and retinoid uptake and recycling [26].”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673 · cited 1×
“Subretinal administration of many of these AAV variants has led to efficient gene expression in a number of retinal neurons and epithelia, including photoreceptors and RPE [14,15], and it is thus the injection route employed by current clinical therapies to achieve sufficient transduction for rescue [2].”
BackgroundThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 4×
“To characterize the in vitro infectivity of these mutants, and in particular their glycan dependence in light of the substantial role proteoglycans and glycoproteins play in AAV transduction [4,5,13], we analyzed their relative transduction efficiencies on a panel of cell types: Pro5, a Pro5 mutant (Lec1) deficient in…”
BackgroundInfluentialLagali, P. S., Balya, D., Awatramani, G. B., Münch, T. A., Kim, D. S., Busskamp, V., Cepko, C. L., & Roska, B. (2008) · Nature Neuroscience · doi:10.1038/nn.2117 · Cited by 582 · cited 1×
“selections could provide a more powerful approach to directly target specific cell types in the retina. For example, the targeting of engineered light gated channels to specific subpopulations of retinal cells, such as ON bipolar cells or ON/OFF retinal ganglion cells”
BackgroundDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 3×
“The resulting viral fractions were desalted and concentrated with Amicon Ultra-15 Centrifugal Filter Units to a final volume of 200 ml. Vector was then titered for DNase-resistant vector genomes by real time PCR relative to a standard.”
MethodSelf-citationInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“. In addition, the capsid diversity found among natural AAV variants, or serotypes, isolated from human and nonhuman primate tissues accounts for its diverse tropisms, as AAV has been shown in animal models to deliver genes to cells in numerous tissues including the retina, brain, muscle, and lung”
Background
Cited by
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Self-citationDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
“This approach, which selected viruses for the ability to penetrate the retina and infect a therapeutically relevant cell, advances on previous work that selected AAV libraries in vitro (41, 42) or selected the virus in vivo for general localization to an organ after injection into the bloodstream (43, 44).”
BackgroundSelf-citationViral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Self-citationPearson, R. A., Gonzalez-Cordero, A., West, E. L., Ribeiro, J. R., Aghaizu, N., Goh, D., Sampson, R. D., Georgiadis, A., Waldron, P. V., Duran, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13029 · Cited by 309
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Optogenetic therapy for retinitis pigmentosa
Busskamp, V, Picaud, S., Sahel, J. A., & Roska, B. (2012) · Gene Therapy · doi:10.1038/gt.2011.155 · Cited by 235
Adeno-associated virus (AAV) vectors in cancer gene therapy
Santiago-Ortiz, J. L., & Schaffer, D. V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.001 · Cited by 228
“AAV vectors have also been evolved for in vivo enhanced tissue spread and infection of non-permissive cell types [49,50].”
BackgroundSelf-citationPharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
“an AAV6 variant, has increased tropism for glial cells following intravitreal delivery and has been shown to rescue retinal function in a rat model of RP (76,77).”
BackgroundVector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“Klimczak et al., 2009; 17.”
MethodNeuron-glia signaling in developing retina mediated by neurotransmitter spillover
Rosa, J. M., Bos, R., Sack, G. S., Fortuny, C., Agarwal, A., Bergles, D. E., Flannery, J. G., & Feller, M. B. (2015) · eLife · doi:10.7554/elife.09590 · Cited by 175
Self-citationKotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169
Self-citationViral Strategies for Targeting the Central and Peripheral Nervous Systems
Bedbrook, C. N., Deverman, B. E., & Gradinaru, V. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-062048 · Cited by 168
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
“In the retina, this technology was used to identify a variant capable of specifically transducing Muller cells via the vitreous [39].”
BackgroundMethodLi, Y., Andereggen, L., Yuki, K., Omura, K., Yin, Y., Gilbert, H.-Y., Erdogan, B., Asdourian, M. S., Shrock, C., de Lima, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616811114 · Cited by 162
“In some studies, intraocularly injected AAV2 expressing an mCherry reporter (AAV2-mCherry, 2 × 1012 GC/mL; gift from Luk Vandenberghe, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, MA) was used to label RGCs, whereas AAV6-mCherry (5 × 1012 GC/mL; Virovek) was used to label retinal interneuron…”
MethodDirected evolution of novel adeno-associated viruses for therapeutic gene delivery
Bartel, M. A., Weinstein, J. R., & Schaffer, D. V. (2012) · Gene Therapy · doi:10.1038/gt.2012.20 · Cited by 162
Self-citationThrombospondin-1 Mediates Axon Regeneration in Retinal Ganglion Cells
Bray, E. R., Yungher, B. J., Levay, K., Ribeiro, M., Dvoryanchikov, G., Ayupe, A. C., Thakor, K., Marks, V., Randolph, M., Danzi, M. C., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.044 · Cited by 155
“Consistent with previous studies (Klimczak et al., 2009), we confirmed that intravitreal injection of AAV-shH10-GFP and AAV-shH10-THBS1 induce transgene expression mostly in Muller cells and not in RGCs (Figures 5K and L).”
InfluentialYao, K., Qiu, S., Tian, L., Snider, W. D., Flannery, J. G., Schaffer, D. V., & Chen, B. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.078 · Cited by 173
“…without Retinal Injury To develop a MG-specific gene transfer method, wemodified an adeno-associated virus (AAV) variant, known as ShH10 (Klimczak et al., 2009; Koerber et al., 2009), by replacing the ubiquitous CAG promoter with the MG-specific promoter GFAP (Kuzmanovic et al., 2003).”
Self-citationControlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“In addition to AAV2-7m8, ShH10 can specifically transduce Müller cells from the vitreous [98].”
BackgroundPluripotent stem cell-derived retinal organoids for disease modeling and development of therapies
Kruczek, K., & Swaroop, A. (2020) · Stem Cells · doi:10.1002/stem.3239 · Cited by 148
Structural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Govindasamy, L., Gurda, B. L., McKenna, R., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje-McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 143
“In contrast, though wild-type AAV6 binds HS, it can transduce cells in the absence of HS but not in the absence of sialic acid (33, 58, 70).”
BackgroundSahel, J.-A., & Roska, B. (2013) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170304 · Cited by 140
“…than 100 different natural capsids, and thousands of genetically modified capsids have been created through rational mutagenesis of the capsid (PetrsSilva et al. 2009, 2011; Zhong et al. 2008) or selected through combinatorial screens (Bartel et al. 2012, Dalkara et al. 2011, Klimczak et al. 2009).”
BackgroundRibeiro, J., Procyk, C. A., West, E. L., O’Hara-Wright, M., Martins, M. F., Khorasani, M. M., Hare, A., Basche, M., Fernando, M., Goh, D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109022 · Cited by 148
Pernet, V., Joly, S., Dalkara, D., Jordi, N., Schwarz, O., Christ, F., Schaffer, D. V., Flannery, J. G., & Schwab, M. E. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.011 · Cited by 133
“An engineeredAAV called ShH10was selected based on its ability to preferentially transduce Müller glia (Klimczak et al., 2009).”
BackgroundMethodSelf-citationNovel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
CRALBP supports the mammalian retinal visual cycle and cone vision
Xue, Y., Shen, S. Q., Jui, J., Rupp, A. C., Byrne, L. C., Hattar, S., Flannery, J. G., Corbo, J. C., & Kefalov, V. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79651 · Cited by 119
Self-citationAsuri, P., Bartel, M. A., Vazin, T., Jang, J.-H., Wong, T. B., & Schaffer, D. V. (2012) · Molecular Therapy · doi:10.1038/mt.2011.255 · Cited by 119
Self-citationPernet, V., Joly, S., Jordi, N., Dalkara, D., Guzik-Kornacka, A., Flannery, J. G., & Schwab, M. E. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.266 · Cited by 124
“AAV (1 ml) were intravitreously injected 4 weeks before optic nerve crush or tissue analysis, a duration of time that allowed optimal transgene expression in vivo.(22,40) To block the activation of ROCK, 2ml of the pharmacological inhibitor Y27632 (3 mM, in PBS) was administered intraocularly at the time of the optic…”
MethodSelf-citationHuman CRB1-Associated Retinal Degeneration: Comparison with the rd8 Crb1-Mutant Mouse Model
Aleman, T. S., Cideciyan, A. V., Aguirre, G. K., Huang, W. C., Mullins, C. L., Roman, A. J., Sumaroka, A., Olivares, M. B., Tsai, F. F., Schwartz, S. B., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7701 · Cited by 116
Engineering the AAV capsid to optimize vector–host-interactions
Büning, H., Huber, A., Zhang, L. N., Meumann, N., & Hacker, U. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.002 · Cited by 127
Dalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N. V., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 110
Self-citationO’Carroll, S. J., Cook, W. H., & Young, D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.618020 · Cited by 107
Grimm, D., & Zolotukhin, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.173 · Cited by 106
A look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 117
In vivo–directed evolution of adeno-associated virus in the primate retina
Byrne, L. C., Day, T. P., Visel, M., Strazzeri, J. A., Fortuny, C., Dalkara, D., Merigan, W. H., Schaffer, D. V., & Flannery, J. G. (2020) · JCI Insight · doi:10.1172/jci.insight.135112 · Cited by 104
Self-citationAdeno-Associated Viral Vectors for Mapping, Monitoring, and Manipulating Neural Circuits
Betley, J. N., & Sternson, S. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.204 · Cited by 104
“One of these mutant capsids efficiently transduced Muller glial cells in the retina with high selectivity over other cell types (Klimczak et al. , 2009).”
Linking YAP to Müller Glia Quiescence Exit in the Degenerative Retina
Hamon, A., García-García, D., Ail, D., Bitard, J., Chesneau, A., Dalkara, D., Locker, M., Roger, J. E., & Perron, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.045 · Cited by 113
Self-citationBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“An example are the rAAV6 variants ShH10 and ShH10-Y445F that efficiently infect rat, mouse, and human Müller glial cells [60,62,272].”
BackgroundJang, J.-H., Koerber, J. T., Kim, J.-S., Asuri, P., Vazin, T., Bartel, M., Keung, A., Kwon, I., Park, K. I., & Schaffer, D. V. (2011) · Molecular Therapy · doi:10.1038/mt.2010.287 · Cited by 101
Self-citationOjala, D. S., Sun, S., Santiago-Ortiz, J. L., Shapiro, M. G., Romero, P. A., & Schaffer, D. V. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.006 · Cited by 97
Self-citationQuinn, P. M., Buck, T. M., Mulder, A. A., Ohonin, C., Alves, C. H., Vos, R. M., Bialecka, M., van Herwaarden, T., van Dijk, E. H. C., Talib, M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.002 · Cited by 97
“Further proof of Müller glial-specific transduction is also seen with the use of ShH10Y445FRLBP1-GFP (Figure 6D), which drives GFP in MGCs in rat and mouse retinas (Klimczak et al., 2009; Pellissier et al., 2014a).”
BackgroundThe CRB1 and adherens junction complex proteins in retinal development and maintenance
Alves, C. H., Pellissier, L. P., & Wijnholds, J. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.01.001 · Cited by 106
Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h−/− mouse
Byrne, L. C., Öztürk, B. E., Lee, T., Fortuny, C., Visel, M., Dalkara, D., Schaffer, D. V., & Flannery, J. G. (2014) · Gene Therapy · doi:10.1038/gt.2014.31 · Cited by 96
Self-citationElsaeidi, F., Macpherson, P. C. D., Mills, E. A., Jui, J., Flannery, J. G., & Goldman, D. J. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2126-17.2018 · Cited by 96
“1016 tuba1a:GFP, gfap:GFP, and tp1:mCherry fish were previously described (Fausett and Goldman, 2006; Kassen et al., 2007; Parsons et al., 2009; Kwon et al., 2010).”
BackgroundSelf-citationDuebel, J., Marazova, K., & Sahel, J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000140 · Cited by 123
“by the virtue of the AAV capsid [46] or transduction of photoreceptors following surgically simple intravitreal injections [31 & ].”
Peynshaert, K., Devoldere, J., Minnaert, A.-K., De Smedt, S. C., & Remaut, K. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1565890 · Cited by 92
“who designed the ShH10 vector, a variant related to AAV6 but with HSPG dependence.(49,55) Remarkably, while ShH10 presented less affinity for HSPG than AAV2, the elicited retinal transduction was higher.”
MethodMüller cells as a target for retinal therapy
Devoldere, J., Peynshaert, K., Smedt, S. C. D., & Remaut, K. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.023 · Cited by 98
Pellissier, L. P., Quinn, P. M., Alves, C. H., Vos, R. M., Klooster, J., Flannery, J. G., Heimel, J. A., & Wijnholds, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv062 · Cited by 86
“The AAV6-derived AAV2/ShH10Y445F or ShH10Y serotype showed increased ability to transduce rat andmouse Müller glial cells after intravitreal injection (22,32).”
BackgroundSelf-citationAAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants
Santiago-Ortiz, J., Ojala, D. S., Westesson, O., Weinstein, J. R., Wong, S. Y., Steinsapir, A., Kumar, S., Holmes, I., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2015.74 · Cited by 83
Self-citationDalkara, D., Byrne, L. C., Lee, T., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2011) · Gene Therapy · doi:10.1038/gt.2011.163 · Cited by 94
Self-citationBoye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
“AAV6 previously has been reported to efficiently transduce inner retina via the vitreous, while AAV1 promotes only limited transduction when delivered via this route (32).”
BackgroundInfluentialGonzalez-Cordero, A., Goh, D., Kruczek, K., Naeem, A., Fernando, M., kleine Holthaus, S.-M., Takaaki, M., Blackford, S. J. I., Kloc, M., Agundez, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.027 · Cited by 77
“42 We performed i.v. injections of the six CMV.GFP viruses into wild-type postnatal day 6 pups, a similar stage to days 22–24 of differentiation, to assess the potential of these viruses to transduce different cell types in the postnatal neural retina (Supplementary Fig.”
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Such approach may be beneficial in cases where the targeted cells are not limited only to the macula.(65,66) There are two main limitations of the intravitreal route: the inability to transduce outer retina layers and possible immune and inflammatory reaction.”
BackgroundChadderton, N., Palfi, A., Millington-Ward, S., Gobbo, O., Overlack, N., Carrigan, M., O'Reilly, M., Campbell, M., Ehrhardt, C., Wolfrum, U., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.112 · Cited by 76
The Role of Müller Cells in Diabetic Macular Edema
Lai, D., Wu, Y., Shao, C., & Qiu, Q. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.10.8 · Cited by 86
Achberger, K., Cipriano, M., Duechs, M. J., Schön, C., Michelfelder, S., Stierstorfer, B., Lamla, T., Kauschke, S. G., Chuchuy, J., Roosz, J., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.08.008 · Cited by 81
“In addition to these well-studied vectors, newly developed variants with reported specific tropism or increased efficacy in preclinical models were evaluated (Klimczak et al., 2009; Pavlou et al., 2021).”
BackgroundByrne, L. C., Khalid, F. I., Lee, T., Zin, E. A., Greenberg, K. P., Visel, M., Schaffer, D. V., & Flannery, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076075 · Cited by 77
“Recently, we developed a novel AAV variant called ShH10 that is closely related to AAV6 and specifically and efficiently targets Müller glia when injected into the vitreous [21,22].”
BackgroundResultSelf-citationAdvances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 71
Self-citationRakoczy, E. P., Magno, A. L., Lai, C.-M., Pierce, C. M., Degli-Esposti, M. A., Blumenkranz, M. S., & Constable, I. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.03.006 · Cited by 70
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 78
“improved glial tropism after intravitreal administration [73].”
Vectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
“An AAV variant capable of targeting exclusive Müller glial targeting via the vitreous has been described and has the advantage of not requiring cell type–specific promoters to obtain restricted gene expression in this cell type (Klimczak et al. 2009).”
BackgroundSelf-citationNew tools for investigating astrocyte-to-neuron communication
Li, D., Agulhon, C., Schmidt, E., Oheim, M., & Ropert, N. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00193 · Cited by 66
“New serotypes have been developed using a directed evolution approach with higher transduction level for astrocytes leading to 94% specific expression in retinal Müller glial cells after intravitreal injection (Klimczak et al., 2009).”
BackgroundCarvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Öztürk, B. E., Johnson, M. E., Kleyman, M., Turunç, S., He, J., Jabalameli, S., Xi, Z., Visel, M., Dufour, V., Iwabe, S., et al. (2021) · eLife · doi:10.7554/elife.64175 · Cited by 66
Self-citationWoodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
“rAAV6 is a serotype of interest for retinal transduction and has been modified to increase the specific transduction of Müller glia using the ShH10 capsid (45).”
MethodSpecific tools for targeting and expression in Müller glial cells
Pellissier, L. P., Hoek, R. M., Vos, R. M., Aartsen, W. M., Klimczak, R. R., Hoyng, S. A., Flannery, J. G., & Wijnholds, J. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.9 · Cited by 58
Self-citationCritical examination of Ptbp1-mediated glia-to-neuron conversion in the mouse retina
Chen, B., Xie, Y., Zhou, J., & Guo, X. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110960 · Cited by 61
“About 1.5 μL NMDA solution (200 mM in PBS), or 1.0 μL of AAV, either ShH10-CMV-LSL-RFP or ShH10-CMV-LSL-RFP-ShPtbp1, was injected into the vitreous body of mouse retinas.”
InfluentialRetinal Ganglion Cell Gene Therapy and Visual System Repair
Hellström, M., & Harvey, A. R. (2011) · Current Gene Therapy · doi:10.2174/156652311794940746 · Cited by 60
“As a further example, a novel rAAV6 variant named ShH10 was recently shown to be almost exclusively specific towards retinal Müller cells [112], while rAAV2/6 otherwise shows a very broad retinal tropism after intravitreal injection [90].”
BackgroundNair, R. R., Blankvoort, S., Lagartos, M. J., & Kentros, C. (2020) · iScience · doi:10.1016/j.isci.2020.100888 · Cited by 55
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52
“Enrichment of one variant, AAV7M8, occurred through repeated cycles of intravitreal injections, followed by photoreceptor harvesting and AAV capsid sequence isolation.(10,31) As a result, AAV7M8 shows unprecedented ability to transduce mouse outer retina from the vitreous.”
Hakim, A. M., Guido, B., Narsineni, L., Chen, D.-W., & Földvári, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114781 · Cited by 56
Promising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2015) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 49
AAV‐mediated gene delivery in Dp71‐null mouse model with compromised barriers
Vacca, O., Darche, M., Schaffer, D. V., Flannery, J. G., Sahel, J., Rendon, A., & Dalkara, D. (2014) · Glia · doi:10.1002/glia.22617 · Cited by 48
“Results ShH10-GFP Targets M€ uller Glial cells in the Wild-type Mouse Retina Previously, the AAV variant ShH10, engineered for specific glial transduction by directed evolution, has been characterized in rat retinas (Klimczak et al., 2009) and has been shown to transduce almost exclusively the M€ uller cells with smal…”
BackgroundMethodInfluentialSelf-citationTargeted ablation of Crb2 in photoreceptor cells induces retinitis pigmentosa
Alves, C. H., Pellissier, L. P., Vos, R. M., Garrido, M. G., Sothilingam, V., Seide, C., Beck, S. C., Klooster, J., Furukawa, T., Flannery, J. G., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu048 · Cited by 50
“For Müller glial cell-specific transduction via the intravitreal route, an AAV2-based vector was packaged in ShH10Y445F capsid (AAV2/ShH10Y) (27,28), 10(10) genome copies of AAV2/ShH10Y CMV-CRE-GFP (1 ml) by intravitreal injection into floxed Crb2 retinas.”
MethodSelf-citationAlqawlaq, S., Huzil, J. T., Ivanova, M. V., & Földvári, M. (2012) · Nanomedicine · doi:10.2217/nnm.12.69 · Cited by 52
Bogner, B., Boye, S. L., Min, S.-H., Peterson, J. J., Ruan, Q., Zhang, Z., Reitsamer, H. A., Hauswirth, W. W., & Boye, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128759 · Cited by 48
“However, the AAV vector toolkit is rapidly expanding and by combining knowledge of AAV capsid sequences with the structures available for these serotypes [78–83] (and unpublished data), it is now possible to delineate determinants of vector function (both intracellular and extracellular) and to rationally design vecto…”
BackgroundEvaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
“Astrocytes may also be involved due to Katada et al. (2019), PeerJ, DOI 10.7717/peerj.6317 6/15 Full-size DOI: 10.7717/peerj.6317/fig-2 the cellular similarity as previously reported (Klimczak et al., 2009).”
InfluentialXie, Y., Zhou, J., Wang, L.-L., Zhang, C., & Chen, B. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104531 · Cited by 50
Aartsen, W. M., van Cleef, K. W. R., Pellissier, L. P., Hoek, R. M., Vos, R. M., Blits, B., Ehlert, E. M. E., Balaggan, K. S., Ali, R. R., Verhaagen, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012387 · Cited by 41
“throughout the retina, not limited to Müller cells aligning the major blood vessels [37].”
BackgroundAdvances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
“Furthermore, the optogenetic modules themselves will improve because of developments in their sensitivity as artificial photoreceptors or as sensors responsive to a wide range of wavelengths, including near-infrared wavelengths [56].”
BackgroundKurzawa‐Akanbi, M., Tzoumas, N., Corral-Serrano, J. C., Guarascio, R., STEEL, D. H., Cheetham, M. E., Armstrong, L., & Lako, M. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101248 · Cited by 44
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids
Furusho, T., Das, R., Hakui, H., Sairavi, A., Adachi, K., Galbraith-Liss, M. S., Rajagopal, P., Horikawa, M., Luo, S., Li, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54475-9 · Cited by 50
Focused ultrasound as a novel strategy for noninvasive gene delivery to retinal Müller glia
Touahri, Y., Dixit, R., Kofoed, R. H., Miloska, K., Park, E., Raeisossadati, R., Markham-Coultes, K., David, L. A., Rijal, H., Zhao, J., et al. (2020) · Theranostics · doi:10.7150/thno.42611 · Cited by 43
“One way to move forward would be to combine different AAVs, such as AAV-ShH10, which is related to AAV6 and has a strong tropism for Müller glia [21, 44, 45], with Müller glia-specific promoter sequences, which together may minimize peripheral organ expression.”
Castro, B. F. M., Steel, J. C., & Layton, C. J. (2023) · BioDrugs · doi:10.1007/s40259-023-00629-y · Cited by 42
“The shH10 AAV capsid was a variant selected to efficiently transduce Müller cells through intravitreal injection [135].”
BackgroundRationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37
The role of RGC degeneration in the pathogenesis of glaucoma
Si, Z., Fan, Y., Wang, M., Zhao, J., Zhang, Y., Liu, D., & Zheng, Y. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.103222 · Cited by 50
Adeno-Associated Virus Mediated Gene Therapy for Retinal Degenerative Diseases
Stieger, K., Cronin, T., Bennett, J., & Rolling, F. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_8 · Cited by 35
Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant
Kotterman, M. A., Vazin, T., & Schaffer, D. V. (2015) · Development · doi:10.1242/dev.115253 · Cited by 36
Self-citationChtarto, A., Bockstael, O., Tshibangu, T., Witte, O. D., Levivier, M., & Tenenbaum, L. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12065 · Cited by 36
“engineered (by random mutagenesis or rationally-designed modifications), have been described [79] [134] [135] [136] [137] [138] [139] [140-143] [144] [145].”
Awakening the regenerative potential of the mammalian retina
Martin, J. F., & Poché, R. A. (2019) · Development · doi:10.1242/dev.182642 · Cited by 34
“Previously, a variant of AAV6 called ShH10 was reported to have very high tropism for adult, rodent MG, but to also infect a subset of NeuN (Rbfox3) ganglion and amacrine cells (Byrne et al., 2013; Klimczak et al., 2009; Yao et al., 2016).”
BackgroundCehajic-Kapetanovic, J., Milosavljevic, N., Bedford, R. A., Lucas, R. J., & Bishop, P. N. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.002 · Cited by 30
Koh, S., Chen, W. J., Dejneka, N. S., Harris, I. R., Lu, B., Girman, S., Saylor, J., Wang, S., & Eroglu, C. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1532-17.2018 · Cited by 29
“John Flannery (University of California–Berkley) (Klimczak et al., 2009).”
MethodInfluentialHippert, C., Graca, A. B., Basche, M., Kalargyrou, A. A., Georgiadis, A., Ribeiro, J., Matsuyama, A., Aghaizu, N. D., Bainbridge, J. W., Smith, A. J., et al. (2021) · Glia · doi:10.1002/glia.24034 · Cited by 31
“While these vectors effectively transduce astrocytes in vitro (see Klimczak et al., 2009 and Figure S2a), transduction of astrocytes in vivo was extremely low and GFAP levels remained robust (Figure S2b and Figure 2ciii,vi).”
BackgroundRetinal Degeneration Progression Changes Lentiviral Vector Cell Targeting in the Retina
Calame, M., Cachafeiro, M., Philippe, S., Schouwey, K., Tekaya, M., Wanner, D., Sarkis, C., Kostic, C., & Arsenijevic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023782 · Cited by 29
Regenerative nanomedicine and the treatment of degenerative retinal diseases
Zarbin, M. A., Montemagno, C. D., Leary, J. F., & Ritch, R. H. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.167 · Cited by 29
Vacca, O., Charles‐Messance, H., Mathari, B. E., Sène, A., Barbe, P., Fouquet, S., Aragón, J., Darche, M., Giocanti‐Auregan, A., Pâques, M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw159 · Cited by 31
“We recently tested an AAV capsid variant, ShH10 that efficiently and specifically transduces Mu¨ller glial cells from the vitreous of the Dp71-null mouse (2,16).”
MethodSelf-citationAAV capsid bioengineering in primary human retina models
Westhaus, A., Eamegdool, S. S., Fernando, M., Fuller-Carter, P. I., Brunet, A. A., Miller, A. L., Rashwan, R., Knight, M., Daniszewski, M., Lidgerwood, G. E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49112-2 · Cited by 32
Adeno-Associated Viral Vectors for Gene Therapy of Inherited Retinal Degenerations
Flannery, J. G., & Visel, M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-62703-080-9_25 · Cited by 26
Self-citationFuentes, C., & Schaffer, D. V. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.003 · Cited by 28
Self-citation
Metadata
- Authors
- Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Flannery, John G.
- Schaffer, David V.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-10-14
- Volume
- 4
- Issue
- 10
- Pages
- e7467
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2758586
- OpenAlex
- W2170160409
- Cited by
- 210
- References
- 49
- Citations by year
- 2026: 12 · 2025: 5 · 2024: 13 · 2023: 15 · 2022: 13 · 2021: 19 · 2020: 12 · 2019: 19 · 2018: 13 · 2017: 12 · 2016: 11 · 2015: 19 · 2014: 12 · 2013: 10 · 2012: 9
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- National Heart, Lung, and Blood Institute (R01HL081527)
- National Eye Institute (PN2EY018241)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, Müller cells, intravitreal injection, retinal degeneration, gene delivery, retinal glia, neuroprotection, AAV tropism, directed evolution
- MeSH terms
- Dependovirus, Animals, Astrocytes, Cell Line, DNA Mutational Analysis, Genetic Vectors, Humans, Neuroglia, Retina, Retinal Diseases, Genetic Therapy, Rats, Sprague-Dawley, Gene Transfer Techniques, Rats, Retinal Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.